Topiramate and Amitriptyline Not Effective for Migraine in Children
Am Fam Physician. 2017 May 15;95(10):online.
Is topiramate (Topamax) or amitriptyline effective for prophylaxis of migraine in children?
Topiramate, amitriptyline, and placebo all led to a similar, substantial improvement in migraine frequency and disability. How to harness this strong placebo effect for our patients is an important, but unanswered, question. (Level of Evidence = 1b)
Migraine is a relatively common problem in children, but until recently there were no U.S. Food and Drug Administration–approved drugs for migraine prophylaxis in children (topiramate was approved in 2014). The most commonly used drugs are amitriptyline and topiramate. However, these drugs had not been studied in a clinical trial. In this study, the researchers enrolled 361 children (eight to 17 years of age) with chronic migraine, at least mild disability, and at least four headache days in a 28-day period. Their mean age was 14 years, 68% were female, and 70% were white. Their mean migraine disability score was 41.4, consistent with moderate severity, and they had a mean of 11 headaches during the 28-day baseline period. Groups were balanced at the start of the study. Participants were randomized in a 2:2:1 ratio to amitriptyline (in a target dosage of 1 mg per kg per day), topiramate (2 mg per kg per day), or placebo (twice per day). The trial was ended early because of futility, leading to some patients contributing only a portion of their headache diary data to the results. The mean migraine disability score decreased (from 41.4) to 19 in the amitriptyline group, 14 in the topiramate group, and 19 in the placebo group. Headache frequency declined similarly in all three groups from a mean of 11 to five. Adverse effects were much more common in the active treatment groups, including dry mouth and fatigue. There was a single suicide attempt in the topiramate group, and none in the other groups.
Study design: Randomized controlled trial (double-blinded)
Funding source: Government
POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Associate Deputy Editor.
A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions